Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test

Biodesix has launched GeneStrat, a PCR-based liquid biopsy test for patients with advanced non-small cell lung cancer. The assay uses BioRad's droplet digital PCR to identify clinically actionable mutations in EGFR, KRAS, and BRAF in circulating tumor DNA, which are useful in guiding targeted therapy treatment decisions in NSCLC.

This includes the EGFR T790M mutation, which is a marker of resistance to anti-EGFR drugs. According to Biodesix, turaround time for the test is 72 hours.